NervGen Presenting Interim Phase 1 Clinical Trial Data for NVG-291 at the 2022 American Academy of Neurology Annual Meeting
Human subjects now being enrolled in the second cohort of multiple ascending dose portion of the studyNVG-291 dose administered in...
XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency